Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy

Lorena Airaghi, Maddalena Lettino, Maria Grazia Manfredi, James Matthew Lipton, Anna Catania

Research output: Contribution to journalArticlepeer-review


We tested the idea that cytokine antagonists are released during acute myocardial ischemia to counteract proinflammatory effects of cytokines. We investigated changes in plasma concentrations of the anticytokine molecules α-melanocyte-stimulating hormone (α-MSH), interleukin-1 receptor antagonist (IL-1 ra), and soluble tumor necrosis factor receptor (sTNFr) in patients with acute myocardial infarction (AMI) or unstable angina (UA). Blood samples were collected at presentation in the coronary care unit, at 3-hour intervals for 24 hours, and daily for 4 days thereafter. There were no significant differences in the concentrations of cytokine antagonists in patients with AMI or UA. However, whereas concentrations of α-MSH were increased in early samples of patients with AMI or UA who were treated with a thrombolytic agent, they were consistently low in untreated patients. IL-1 ra concentrations likewise were greater 3 and 6 hours after treatment in patients who underwent thrombolysis, whereas there was no significant difference in plasma sTNFr between the two groups. We suggest that during myocardial ischemia and thrombolysis anticytokine molecules released from the injured myocardium become available to reduce inflammation caused by cytokines and other mediators of inflammation.

Original languageEnglish
Pages (from-to)204-211
Number of pages8
JournalAmerican Heart Journal
Issue number2
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy'. Together they form a unique fingerprint.

Cite this